Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833746 | 0.90 | KCNK2 (0.39) | S1PR1S1PR3MPOHIF1AMAP2K1 | |
| SCHEMBL6833954 | 0.87 | RORC (0.35) | TAS2R14RXFP1S1PR1S1PR3MPO | |
| SCHEMBL6818600 | 0.82 | TP53 (0.34) | TAS2R14S1PR1S1PR3MPOHIF1A | |
| SCHEMBL6818246 | 0.80 | TP53 (0.34) | TAS2R14S1PR1S1PR3TP53MAP2K1 | |
| SCHEMBL6821982 | 0.80 | TP53 (0.34) | TAS2R14S1PR1S1PR3TP53 | |
| SCHEMBL6822026 | 0.80 | EGLN2 (0.35) | TAS2R14S1PR1S1PR3MPOTP53 | |
| SCHEMBL6822667 | 0.80 | RORC (0.37) | S1PR1S1PR3MAP2K1 | |
| SCHEMBL6818889 | 0.79 | EGLN2 (0.34) | TAS2R14S1PR1S1PR3MPOTP53 | |
| SCHEMBL6819469 | 0.79 | RORC (0.36) | S1PR1S1PR3MAP2K1 | |
| SCHEMBL6818406 | 0.79 | RORC (0.34) | TAS2R14S1PR1S1PR3MPOTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | TAS2R14 1288/4885RXFP1 3523/4885CA12 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.